A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Takeda

Status and phase

Completed

Phase 4

Conditions

Essential Hypertension Complicated by Type 2 Diabetes Mellitus

Treatments

Drug: Azilsartan

Drug: Telmisartan

Study type

Interventional

Funder types

Industry

Identifiers

NCT02079805

AZI-P4-004 (Other Identifier)

279/NRP-001

U1111-1151-7168 (Registry Identifier)

JapicCTI-142461 (Registry Identifier)

Details and patient eligibility

About

Multicenter, randomized, open-label, parallel-group exploratory study to explore the effects of azilsartan (Azirva), compared with telmisartan, on insulin resistance in participants with essential hypertension complicated by type 2 diabetes mellitus

Full description

The primary objective of the present study is to explore the effects of azilsartan 20 mg, compared with telmisartan 40 mg, once daily orally for 12 weeks on insulin resistance in participants with essential hypertension complicated by type 2 diabetes mellitus.

Enrollment

33 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The participant was given the diagnosis of grade I or II essential hypertension and was judged by the principal investigator or investigator that they can be appropriately treated with azilsartan 20 mg and telmisartan 40 mg.
Sitting systolic blood pressure of ≥ 130 mmHg and < 180 mmHg or sitting diastolic blood pressure of ≥ 80 mmHg and < 110 mmHg at the start of the treatment period (Week 0) Sitting blood pressure will be measured until 2 consecutive stable measurements are obtained (i.e., the difference between 2 measurements: diastolic blood pressure of <5 mmHg and systolic blood pressure of < 10 mmHg) after resting in a sitting position for at least 5 minutes. The average value of the last 2 measurements will be recorded (the first the decimal place is rounded off).
Type 2 diabetes mellitus
HbA1c (NGSP (National Glycohemoglobin Standardization Program) value) of < 8.4% during 3 months before informed consent, with a ≤ 0.3% change in HbA1c (peak minus nadir) during 3 months before informed consent
No change in diet/exercise therapy during the 3 months before the informed consent in a participant who has been on diet/exercise therapy and instructed to improve life style (e.g., diet and exercise)
Age ≥ 20 years at the time of consent
Outpatients
Capable of providing written consent before participation in this study.

Exclusion criteria

Grade III essential hypertension (i.e., sitting systolic blood pressure 180 mmHg or sitting diastolic blood pressure ≥ 110 mmHg), secondary hypertension, or malignant hypertension.
Grade II essential hypertension (i.e., sitting systolic blood pressure ≥ 160 mmHg or sitting diastolic blood pressure ≥ 100 mmHg) for which antihypertensive drug(s) are used
Use of oral antihypertensive medication within 2 weeks before the start of the treatment period Participants who are on any antihypertensive agent at the time of informed consent can be enrolled in the study only after 2-week washout following informed consent.
Use of RAS inhibitors or thiazolidines within 3 months before the start of the treatment period
Type 1 diabetes mellitus
Fasting blood glucose of < 180 mg/dL and HOMA-R of ≤ 1.6 at the start of the treatment period (Week 0)
Receiving or requiring any of the following at the time of informed consent:
- Insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, or other parenteral hypoglycemic agents
- Combination therapy with 3 or more oral hypoglycemic agents
Change of antidiabetic medication (including dosage change) within 3 months before the start of the treatment period
Having diagnosed/treated any of the following cardiovascular diseases within 3 months before the start of the treatment period:
- Cardiac disease/condition: myocardial infarction, coronary revascularization procedure
- Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack
- Advanced hypertensive retinopathy (retinal bleeding or oozing, papilloedema)
Having diagnosed/treated for any of the following cardiovascular diseases more than 3 months before the start of the treatment period, and is now still in unstable condition.
- Cardiac disease/condition: myocardial infarction, coronary revascularization procedure
- Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack
Past or current history of any of the following cardiovascular diseases.
- Cardiac valve stenosis
- Angina pectoris requiring medication
- Congestive cardiac failure requiring medication
- Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation)
- Arteriosclerosis obliterans with intermittent claudication or other symptoms
Have severe ketosis, diabetic coma or precoma, severe infection, or serious trauma
Clinically evident renal disorder (e.g., eGFR <30 mL/min/1.73 m2)
Markedly low bile secretion or severe hepatic disorder
History of hypersensitivity or allergy to azilsartan or telmisartan or to both.
Presence of hyperkalemia (potassium level ≥ 5.5 mEq/L on laboratory testing)
Currently participating in any other clinical study.
Pregnant women, women with possible pregnancy, or breast-feeding women.
Other participants who are inappropriate for participation in this study in the opinion of the principal investigator or investigator.